8:45am ET
Investing
Mitsui Sumitomo Continues to Build WR Berkley Stake
W.R. Berkley and Navan have just seen some huge insider purchases. have seen some huge insider purchases, and there were some other notable insider purchases as well.
Companies
/Healthcare
Zentalis Pharmaceuticals Inc
$3.80
▼ $0.08 (−2.06%) today
Markets closed · 9:33pm ET
Today · % change
Fundamentals
Market Cap
$367.3M
Revenue (TTM)
$26.9M
EPS (TTM)
$-1.95
52-Week Range
$1 – $7
Street Target
$6.89
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Inc is a New York-based biopharmaceutical company focused on developing innovative small molecule treatments for cancer. With a robust pipeline, including ZN-c3 for various solid tumors and hematological malignancies, and ZN-d5 for blood-related disorders, Zentalis is at the forefront of cancer therapy research. Their work spans multiple clinical trial stages, targeting conditions like ovarian, colorectal, and pancreatic cancers. Collaborating with industry giants like Pfizer and GlaxoSmithKline, Zentalis is committed to advancing cancer treatment options through scientific discovery and strategic partnerships.
